A multi-center, randomized, double-blind, placebo- and positive-control, double-dummy, 3 parallel cohort, two-way crossover single oral dose study in GERD (gastro esophageal reflux disease) patients to evaluate the effects of AFQ056 and baclofen (positive control) on the incidence of meal-induced gastro esophageal reflux events
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Mavoglurant (Primary) ; Baclofen
- Indications Gastro-oesophageal reflux
- Focus Therapeutic Use
- 18 Jun 2007 Status change from recruiting to completed
- 11 Jan 2007 New trial record.